In addition, the detection of tumor protein p53 (TP53) mutations (linked to an inferior prognosis and lower response to chemotherapy) (8), or the assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (useful to guide the use of alkylating agents), represent further molecular biomarkers deserving of careful investigation in diffuse low or high grade gliomas (9). The gene discussed is TP53; the disease is central nervous system cancer.